Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=8
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=8
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=8
PubPharm (7.806)
71
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma : A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
72
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma : A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
73
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
74
National Cancer Institute "Cancer Moonshot Biobank" : Cancer Moonshot Biobank Research Protocol
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
75
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
76
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
77
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
78
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1/2 Study of JNJ-64007957, a Humanized BCMA * CD3 Bispecific Antibody in Japanese Patients With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
79
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma : A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
80
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. : A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
3
4
5
6
7
8
9
10
11
12
13
Nächster »
[781]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
7.806
Aufsätze
7.806
E-Artikel
7.806
E-Ressourcen
Zeitschriftentitel
4.588
WHO International Clinical Trials Registry Plat...
3.218
ClinicalTrials.gov
Thema
7.806
610
6.935
Study Type: Interventional
3.170
Multiple Myeloma
2.647
Neoplasms, Plasma Cell
2.056
Recruitment Status: Not yet recruiting
1.944
Phase: Phase 2
1.671
Phase: Phase 3
1.520
Recruitment Status: Completed
1.376
Recruitment Status: Authorised-recruitment may ...
1.327
Recruitment Status: Recruiting
1.007
Medical Condition: Multiple Myeloma
985
Phase: Phase 1
775
Study Type: Observational
471
Recruitment Status: Active, not recruiting
397
Lymphoma
380
Recruitment Status: Terminated
316
Leukemia
258
Phase: Phase 1/Phase 2
250
Myelodysplastic Syndromes
234
Phase: Phase 1, Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4.854
2020-
2.898
2010-2019
54
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7.676
Englisch
88
Unbestimmt
14
Spanisch
8
Dänisch
8
Französisch
6
Deutsch
2
Tschechisch
2
Galizisch
2
Kinyarwanda
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...